SCHEMBL3452363

SCHEMBL3452363

[CH2]c1ccc(CCCN2CCC(O)CC2)cc1

nearest known ligand 0.60

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SPHK1 Q9NYA1 1/20 0.60
SIGMAR1 Q99720 6/20 0.49
ACHE P22303 1/20 0.47
HRH3 Q9Y5N1 1/20 0.47
HRH1 P35367 1/20 0.45
CCR3 P51677 1/20 0.44
MEN1 O00255 1/20 0.44
TP53 P04637 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
TSHR P16473 1/20 0.44
CYP2C19 P33261 1/20 0.44
KMT2A Q03164 1/20 0.44
LTA4H P09960 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4688942 0.85 SPHK1 (0.61) SPHK1SIGMAR1
SCHEMBL15650736 0.84 SIGMAR1 (0.60) SPHK1SIGMAR1ACHEHRH3HRH1
SCHEMBL7550067 0.84 SPHK1 (0.60) SPHK1CYP1A2CYP3A4CYP2D6
SCHEMBL7983946 0.83 SIGMAR1 (0.70) SPHK1SIGMAR1CCR3MEN1TP53
Hydrochloric Acid SCHEMBL7986320 0.83 SPHK1 (0.58) SPHK1CYP1A2CYP3A4CYP2D6
SCHEMBL15922482 0.81 SPHK1 (0.89) SPHK1SIGMAR1ACHEHRH1MEN1
SCHEMBL3451698 0.80 SIGMAR1 (0.63) SIGMAR1HRH3HRH1LTA4H
SCHEMBL6423551 0.80 SIGMAR1 (0.63) SIGMAR1HRH3HRH1LTA4H
SCHEMBL10438853 0.79 SIGMAR1 (0.69) SPHK1SIGMAR1CCR3MEN1TP53
SCHEMBL15921870 0.78 SPHK1 (0.89) SPHK1SIGMAR1HRH1CCR3MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7820818-B2 Heteroaryl nitrile derivatives NOVARTIS AG (CH) 2010-10-26 US disclosed
US-20090227596-A1 HETEROARYL NITRILE DERIVATIVES NOVARTIS AG (CH) 2009-09-10 US disclosed
US-7544688-B2 Hetereoaryl nitrile derivatives NOVARTIS AG (CH) 2009-06-09 US disclosed
EP-1537111-B1 HETEREOARYL NITRILE DERIVATIVES NOVARTIS AG (CH) 2007-05-02 EP disclosed
US-20060142575-A1 Hetereoaryl nitrile derivatives NOVARTIS AG (CH) 2006-06-29 US disclosed
EP-1537111-A1 HETEREOARYL NITRILE DERIVATIVES Novartis AG (CH) 2005-06-08 EP disclosed
WO-2004020441-A1 HETEREOARYL NITRILE DERIVATIVES NOVARTIS AG (CH) 2004-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227596-A1 HETEROARYL NITRILE DERIVATIVES CTSK, CTSS, CTSZ SPHK1 688/4885SIGMAR1 1763/4885ACHE 715/4885
US-20060142575-A1 Hetereoaryl nitrile derivatives CTSK, CTSZ, CTSE SPHK1 952/4885SIGMAR1 1959/4885ACHE 499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.